Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Meletios-Athanasios Dimopoulos, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2024-203910

Published: 2024

Journal Articles

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Panagiotis Malandrakis, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2024-202610

Published: 2024

Journal Articles

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Tina Bagratuni, Christos Vlachos, Maria Sakkou, Ioannis Kollias, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Christine-Ivy Liacos, Kostantina Taouxi, Alexandra Papadimou, Katerina Chrisostomidou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2024-200652

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Giovanni O. Palladini

Blood (2024) 144 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2024-202932

Published: 2024

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Panagiotis Malandrakis, Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Irene Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Kostantina Taouxi, Alexandra Papadimou, Christine-Ivy Liacos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2024-203751

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Blood (2024) 144 (Supplement 1): 7012.

https://doi.org/10.1182/blood-2024-200679

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Panagiotis Malandrakis, Alexandros Briasoulis, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Vasiliki Spiliopoulou, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2024-202627

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Despina Fotiou, Foteini Theodorakakou, Irene Solia, Maria Gavriatopoulou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2024-203853

Published: 2024

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni O. Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2024) 144 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2024-203254

Published: 2024

Journal Articles

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Efstathios Kastritis, Panagiotis Malandrakis, Irene Solia, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Christine-Ivy Liacos, Nefeli Mavrianou Koutsoukou, Katerina Chrisostomidou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 4675.

https://doi.org/10.1182/blood-2024-203858

Published: 2024

Journal Articles

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Roussou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Asimina Papanikolaou, Charikleia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4674.

https://doi.org/10.1182/blood-2024-203780

Published: 2024

Journal Articles

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 4673.

https://doi.org/10.1182/blood-2024-203776

Published: 2024

Journal Articles

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Ismail Elalamy, Elisabeth Mbemba, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 5404.

https://doi.org/10.1182/blood-2023-187055

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Elisabeth Mbemba, Ismail Elalamy, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2023-186645

Published: 2023

NARROW

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only